CINECA IRIS Institutional Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishGlucose-6-phosphate dehydrogenase (G6PD) deficiency represents one of the most common erythrocyte enzymopathy. In the era of drug-eluting stents (DESs), the use of prolonged dual antiplatelet therapy (DAPT) with aspirin (ASA) and thienopyridine (clopidogrel or ticlopidine) has become mandatory in the treatment of patients with acute coronary syndromes (ACS) and/or after percutaneous coronary intervention (PCI). However, the use of ASA, and more in general of antiplatelet drugs in patients with G6PD deficiency remains controversial, also for the absence of specific guidelines and scientific evidences. In the present manuscript, we reviewed the few cases available in medical literature, regarding patients with G6PD deficiency treated with percutaneous coronary artery intervention (PCI) and DAPT, with the aim to discuss and clarify the optimal treatment in these patients.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
| Data di pubblicazione: | 2017 | |
| Titolo: | Antiplatelet therapy in patients with glucose-6-phosphate dehydrogenases deficiency after percutaneous coronary intervention: A reappraisal for clinical and interventional cardiologists | |
| Autori: | Zuin, Marco; Rigatelli, Gianluca; Carraro, Mauro; Galasso, Maria Paola; Dell'Avvocata, Fabio; Paolini, Rossella; Zuliani, Giovanni; Roncon, Loris | |
| Rivista: | CARDIOVASCULAR REVASCULARIZATION MEDICINE | |
| Keywords: | Acute coronary syndrome; Antiplatelet therapy; G6PHD deficiency; Percutaneous coronary artery intervention; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Glucosephosphate Dehydrogenase Deficiency; Humans; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Treatment Outcome; Cardiologists; Percutaneous Coronary Intervention; Radiology, Interventional; Cardiology and Cardiovascular Medicine | |
| Abstract in inglese: | Glucose-6-phosphate dehydrogenase (G6PD) deficiency represents one of the most common erythrocyte enzymopathy. In the era of drug-eluting stents (DESs), the use of prolonged dual antiplatelet therapy (DAPT) with aspirin (ASA) and thienopyridine (clopidogrel or ticlopidine) has become mandatory in the treatment of patients with acute coronary syndromes (ACS) and/or after percutaneous coronary intervention (PCI). However, the use of ASA, and more in general of antiplatelet drugs in patients with G6PD deficiency remains controversial, also for the absence of specific guidelines and scientific evidences. In the present manuscript, we reviewed the few cases available in medical literature, regarding patients with G6PD deficiency treated with percutaneous coronary artery intervention (PCI) and DAPT, with the aim to discuss and clarify the optimal treatment in these patients. | |
| Digital Object Identifier (DOI): | 10.1016/j.carrev.2016.11.011 | |
| Handle: | http://hdl.handle.net/11392/2384923 | |
| Appare nelle tipologie: | 03.1 Articolo su rivista |
File in questo prodotto:
Copyright © 2022